GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Latest Information Update: 30 Aug 2022
Price :
$35 *
At a glance
- Drugs Acimtamig (Primary)
- Indications Hodgkin's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms GHSG-AFM13
- 01 Aug 2022 Final Results published in the Leukemia and Lymphoma
- 08 Dec 2020 Protocol was amended for all further patients received 7 mg per kg per week, with 1 mg per kg loading dose and 6 mg per kg as continuous infusion for 5 days/ week thereafter (Arm C).
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology